Tuhura Biosciences, Inc. · NASDAQ:HURA
Tuhura Biosciences — Investor Presentation (May 2026)
23 slides from Tuhura Biosciences's investor presentation, May 15, 2026
Slide 1: Overcoming Resistance to Cancer Immunotherapy
URA biosciences Overcoming Resistance to Cancer Immunotherapy May 2026 tuhurabio.com
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation includes “forward-looking statements” under the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, and TUHURA’s actual results may differ from its expectations, estimates and projections expressed in its forwa
Slide 3: We are a Phase 3 immuno-oncology company
We are a Phase 3 immuno- oncology company developing three distinct novel technologies and therapeutics to overcome primary and acquired resistance to cancer immunotherapies PUHURA biosciences
Slide 4: Investment Highlights
Investment Highlights Overcoming resistance to cancer immunotherapies IFx-2.0 in a Ph3 accelerated approval study in 1st Line Merkel Cell Carcinoma * Top-line data expected 2H 2027 * Confirmatory trial not expected to be required * Special Protocol Assessment (SPA) Agreement with the FDA VISTA inhib
Slide 5: $50 Million Credit Facility & Royalty Transaction
$50 Million Credit Facility & Royalty Transaction Non-equity $50mm facility to fund all upcoming program milestones through IFx-2.0 Phase 3 Results * Provides Optionality: Capital market independence and into 2028 TuHURA controls amounts of monthly draws if any and retains ability to access capital
Slide 6: Diversified Immuno-Oncology Pipeline
Diversified Immuno-Oncology Pipeline PROGRAM Innate Immune Agonists TME Modulators Negative Immune Regulators TME Modulators MDSC Inhibitors DRUG CANDIDATE IFx-2.0 Innate Immune Agonist TBS-2025 VISTA inhibiting mAb! Bi-specific ADCs INDICATION 1st Line Merkel Cell Cancer Keytruda® +/- IFx-2.0 or pl
Slide 7: IFx Technology: Innate Immune Agonists
URA biosciences IFx Technology Innate Immune Agonists Designed to Overcome Primary Resistance to Checkpoint Inhibitors
Slide 8: IFx-2.0: Mechanism of Action
IFx-2.0: Mechanism of Action Making a Tumor Look Like a Bacterium Initiation of an Innate Immune Response Activation of Tumor Specific T Cells H Allows CPI to work where they previously failed Intra-tumoral injection of pDNA results in expression bacterial protein on surface of tumor — making tumor
Slide 9: Advanced Metastatic Merkel Cell Carcinoma
Advanced Metastatic Merkel Cell Carcinoma 50% of Patients Don’t Respond to 1st Line Keytruda® biosciences a ‘\ FF Keytruda® (pembrolizumab) is the ™ line standard of care for Probability of disease progression at advanced metastatic MCC two years is 26%, 57% and 100% for e those with CR, PR and SD,
Slide 10: Phase 1b Study in Advanced Skin Cancer
Phase 1b Study in Advanced Skin Cancer (Merkel Cell and Cutaneous Squamous Cell Carcinoma) f~ \ \Y Safety Evaluable D hedul Enrolled n=23 (n=21) TRAES ose and Sohedule (13 MCC, 10 SCC) Grade 1 35% (8) : : : Grade 3 4% (1) 1-3 lesions, Weekly x 3 {~ \Y \Y ™ Response Evaluable Best Overall Median Dura
Slide 11: IFx-2.0 Phase 1b Advanced, Metastatic Merkel Cell Carcinoma
IFx-2.0 Phase 1b Advanced, Metastatic Merkel Cell Carcinoma Encouraging durable responses in CPI resistant MCC a aS 15 Patient PD § PR 6 Pm « 13 EE ve 0 5 10 15 20 25 30 35 IFx-2.0 Administration Months Response to CPI Pre IFx-2.0 URA Response to CPI Post IFx-2.0 biosclences 40 11
Slide 12: IFx-2.0 Phase 1b Trial in Advanced Metastatic Merkel Cell Carcinoma
IFx-2.0 Phase 1b Trial in Advanced Metastatic Merkel Cell Carcinoma Progressed through 3 months of Post IFx-2.0 Keytruda® Progressed through 2 months of Post IFx-2.0 rechallenged with Keytruda® (pembrolizumab). (pembrolizumab) rechallenge. Keytruda’. Large bulky abdominal checkpoint inhibitor, Baven
Slide 13: Single Phase Accelerated Approval Trial
Single Phase 3 Accelerated Approval Trial Designed with OCE' — Utilized Project Front Runner Initiative 15 line CPI naive, advanced/metastatic MCC 1:1 Randomization, Placebo, Injection Controlled Trial Primary Endpoint Overall Response Rate (ORR) eco A ant esta Key Secondary Endpoint Progression Fre
Slide 14: TBS-2025 VISTA Inhibiting mAb
biosciences TBS-2025 VISTA Inhibiting mAb
Slide 15: Targeting VISTA: a new checkpoint target in AML, MDS
Targeting VISTA: a new checkpoint target in AML, MDS Strategic Focus and Technology Synergies Synergy with Delta Opioid Receptor ADC. technology targeting MDSCs in blood related cancers Phase 1b/2 novel drug candidate for AML/MDS * Formerly KVA12123 Broad Potential in Blood Related Malignancies VIST
Slide 16: TBS2025: Scientific Rationale for VISTA in AML
TBS2025: Scientific Rational for VISTA in AML * Only checkpoint highly expressed in AML * Expression driven by most common mutations in AML (NPM1, FLT-3) * Presence on leukemic blast in patients correlates with poor survival ¢ Suppression of T cell activity by VISTA on leukemic blasts results in imm
Slide 17: TBS2025: A novel VISTA inhibiting antibody
TBS2025: A novel VISTA inhibiting antibody FDA guidance: r/r AML with no effective or approved therapies ¢ Phase 1b mufNPM1 r/r AML: Abbreviated dose escalation for PK and RPD2 * 75% of patients don't respond to or relapse following menin inhibitors ° Represents an unmet medical need patient populat
Slide 18: Bi-specific ADCs
URA biosciences fodiens ADCs First in class immune modulating ADCs targeting MDSCs and Tregs
Slide 19: First-in-Class Immune Modulating Bi-specific ADCs
We Are Developing a First-in-Class Immune Modulating Bi-functional, Bi- specific Antibody Drug Conjugates (ADC) Targeting MDSCs, Tregs to overcome acquired resistance to cancer immunotherapies cr Non tumor targeting, non internalizing, non cytotoxic or cell cycle targeting payloads Bi-specific: Targ
Slide 20: Delta Opioid Receptor controls immune suppressing genes in MDSCs, Tregs
Delta Opioid Receptor controls the expression of multiple immune suppressing genes in MDSCs, Tregs * MDSCs Produce a cascade of immune suppressing factors (INOS, COXz2, IDO) Attract other immune suppressing cells Tregs * Blocking DOR inhibits immune suppressing genes » MDSCs (iNOS, COX2, ROS) * Treg
Slide 21: Upcoming Milestone Targets
Upcoming Milestone Targets IFx-2.0 Innate Immune Agonist TBS-2025 VISTA Inhibiting mAb MDSC Inhibitors Bi-specific ADCs URA biosciences 2026 1H 2026 Orphan Drug Designation MCC. Planned FDAIND Mtg re development plan Ph 1b/2 trial 2H 2026 Orphan Drug Designation AML Initiate from Ph 1b/2 trial VISTA
Slide 22: Investment Highlights
Investment Highlights Overcoming resistance to cancer immunotherapies IFx-2.0 in a Ph3 accelerated approval study in 1st Line Merkel Cell Carcinoma * Top-line data expected 2H 2027 * Confirmatory trial not expected to be required * Special Protocol Assessment (SPA) Agreement with the FDA VISTA inhib
Slide 23: Overcoming Resistance to Cancer Immunotherapy
URA ‘ biosciences Overcoming Resistance to Cancer @ Immunotherapy tuhurabio.com
TuHURA Biosciences — Investor Presentation (May 2026) on 6ix